Clinical trials
catalyst calendar across sponsors →Studies where NVCT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 5 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, Schonfeld Strategic Advisors LLC) · FINRA short interest 7.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686Number of patients with treatment related adverse events and/or clinical laboratory abnormalitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: NXP900 | Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma | 140 | Mar 2027 | ≤ 224 d | 2026-07-09 |
| Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerNCT07315113Number of patients with treatment related adverse events and/or clinical laboratory abnormalitiesOpen-label · Treatment | Phase 1 | Recruiting | Drug: NXP900, Osimertinib | EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | 18 | Dec 2026 | ≤ 134 d | 2026-07-09 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNCT05226507Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to various reasons impacting the feasibility of future clinical development | Drug: NXP800 | Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation | 45 | 2025-01-01actual | — | 2026-08-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19